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AbstrAct
Hyperprolactinaemia is a common endocrine abnormality in patients with kidney failure. A 43-year-old female, 
known with kidney failure on maintenance haemodialysis, was referred with symptomatic hyperprolactinaemia. 
Biochemical investigations revealed a markedly elevated serum prolactin level. Magnetic resonance imaging of the 
brain (without gadolinium) demonstrated a pituitary macroadenoma. The patient was started on cabergoline 
therapy. This case discusses hyperprolactinaemia in kidney failure and highlights the importance of investigating 
markedly elevated prolactin levels. In cases where patients have galactorrhoea, headaches and/or visual disturbances, 
clinicians should be alert to the possibility of a prolactin-secreting pituitary tumour.
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INtrODUctION
Hyperprolactinaemia is a common biochemical finding 
associated with pituitary tumours, medication, pituitary 
stalk disorders, pregnancy, primary hypothyroidism, chest-
wall lesions (in the T4 dermatome) and kidney failure [1]. 
They are the commonest hormone-secreting pituitary 
tumour in adults [2]. 
Macroprolactinomas measure more than 10 mm in dia-
meter, whereas microprolactinomas are less than 10 mm 
[3]. The clinical manifestations of hyperprolactinaemia 
vary depending on the patient’s age and sex. Females 
typically present with galactorrhoea and oligo/amenor-
rhea whereas men complain of erectile dysfunction and 
loss of libido [4]. Symptoms of mass effect, such as 
headaches, visual field disturbances and cranial neuro-
pathies, may also be observed [2]. Serum prolactin levels 
correlate with the aetiology; a prolactin level greater than 
250 µg/L is indicative of a prolactinoma whereas a level 
of more than 500 µg/L is diagnostic of a macroprolacti-
noma [3].
Hyperprolactinaemia is a common endocrine abnormality 
in patients with kidney failure [4,5]. In patients with 
hyperprolactinaemia who present with headaches and 
visual abnormalities, a high index of suspicion should be 
maintained for a prolactinoma. This case report highlights 
that patients with extremely high prolactin levels, despite 
kidney failure, need to be investigated for a prolactinoma. 
cAsE DEscrIPtION 
A 43-year-old female was referred to the endocrine 
department for workup of hyperprolactinaemia. She 
reported secondary amenorrhoea for two years, recent 
onset of headaches, visual disturbances and bilateral 
galactorrhoea. 
Regarding her past medical history, she had kidney failure 
secondary to hypertension and had been treated with 
chronic haemodialysis (thrice-weekly sessions of 4 hours 
each) since 2018. She had human immunodeficiency 
virus infection, which was virologically suppressed on 
abacavir, lamivudine and efavirenz. Her other chronic 
medications included hydralazine, furosemide, atenolol, 
doxazosin, amlodipine and one-alpha vitamin D. She was 
not pregnant. 
Examination revealed spontaneous galactorrhoea. The 
neurological examination was normal, with no bitemporal 
hemianopia. The rest of the clinical examination was 
unremarkable. Biochemical investigations revealed a pro-
lactin level of 603.7 μg/L (normal range 4.8–23.3 µg/L). 
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The rest of her biochemical workup, including previous 
elevated prolactin levels, are shown in Table 1.
Based on the elevated prolactin levels, which were out of 
keeping with kidney failure, magnetic resonance imaging 
(MRI) of the brain was performed. Gadolinium-based 
contrast was not used, to avoid the risk of nephrogenic 
systemic fibrosis. The MRI showed a sellar mass, measuring 
15 mm transverse x 10 mm anteroposterior x 7 mm 
craniocaudal (Figure 1). A diagnosis of a prolactin-secreting 
pituitary adenoma (macroprolactinoma) was made and the 
patient was started on cabergoline therapy. 
DIscUssION
The prevalence of hyperprolactinaemia in patients with 
kidney failure ranges between 52–81% [5-8]. Hyperpro-
lactinaemia is found in patients undergoing both haemo-
dialysis and peritoneal dialysis [7]. Higher serum prolactin 
levels are described in females [8,9]. However, there is no 
clear association between serum prolactin level and patient 
age, the type of dialysis or the frequency of dialysis [8]. 
Prolactin levels increase as kidney function decreases, with 
the highest prolactin levels seen in patients with kidney 
failure on regular haemodialysis [10]. There is no difference 
in prolactin levels pre- and post-haemodialysis [11], or with 
thrice-weekly versus six-times per week dialysis [8]. The 
mean serum prolactin in patients on both haemodialysis 
and peritoneal dialysis ranges from 33.2–65.2 µg/L [5,7,8]. 
The maximum prolactin levels in patients on haemodialysis 
ranges between 126.6–346.5 µg/L [5,7,10]. 
The precise pathophysiology causing hyperprolactinaemia 
in kidney failure is unknown but is likely multifactorial. The 
first mechanism is related to reduced glomerular filtration 
rate (GFR), as prolactin clearance is reduced by 33% in 
kidney failure [12] and prolactin levels are shown to 
normalise six months post kidney transplant [13]. Addi-
tional mechanisms are independent of GFR. There is 
alteration of dopaminergic pathways, evidenced by resis-
tance of dopamine to both stimulation and suppression 
[5,9,12,14]. This has been attributed to dopamine receptor 
downregulation [12], illustrated by a blunted response of 
prolactin to thyrotropin-releasing hormone [9] and failure 
to suppress prolactin with a single dose of bromocrip- 
tine [9] or dopamine infusion [12]. However, a six-week 
course of bromocriptine has been shown to suppress 
prolactin [9]. In patients with kidney failure, the circadian 
rhythm of prolactin disappears, and they have diminished 
physiological  oscillations of prolactin secretion, leading to a 
longer half-life of prolactin. This, coupled with a lower 
clearance rate, results in elevated prolactin levels [15]. 
Other postulated mechanisms include total body zinc 
depletion and secondary hyperparathyroidism [14].
In patients with kidney failure who present with hyper-
prolactinaemia, drugs need to be excluded as a cause. 
Drugs commonly used in kidney failure that may cause 
hyperprolactinaemia include anti-hypertensives (verapamil 
and α-methyldopa), antidepressants, metoclopramide and 
antihistamines [1,3,9]. 
table 1.  Biochemical investigations in a patient with a macroprolactinoma.
2 years before  
presentation
1 year before  
presentation
at current  
presentation reference range
Urea (mmol/L) 25.1 2.1–7.1 
Creatinine (µmol/L) 632 49–90 
Estimated glomerular filtration rate  
(mL/min/1.73 m2)
6 >89 
Prolactin (µg/L) 293.8 287.6 603.7 4.8–23.3 
Monomeric prolactin (µg/L) 432.4 3.5–18 
Parathyroid hormone (pmol/L) 86.1 1.6–6.0 
Thyroid stimulating hormone (mIU/L) 1.53 0.35–5.5 
Thyroxine (pmol/L) 18.1 11.5–22.7 
Adrenocorticotropic hormone (pmol/L) 2.8 1.6–13.9 
Follicle stimulating hormone (IU/L) 4.5 
Luteinising hormone (IU/L) 0.7 
Oestradiol (pmol/L) <19 
Human growth hormone (µg/L 0.9 
Insulin-like growth factor (µg/L) 115 58–219 
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Once drug causes have been excluded, an MRI scan is nec-
essary to exclude a prolactinoma. The Endocrine Society 
guidelines recommend medical treatment with a dopamine 
agonist as first-line therapy for all prolactinomas [3]. Both 
cabergoline and bromocriptine may be used in patients 
with kidney failure [4,6]. Cabergoline and bromocriptine 
are renally excreted in the order of 20% and 6%, respec-
tively, and hence require no dose adjustment. Cabergoline 
is recommended, as it has greater efficacy in normalising 
prolactin levels and shrinkage of tumour size [3].
cONcLUsIONs AND LEArNING POINts
A significant proportion of patients with kidney failure have 
hyperprolactinaemia, usually less than 100 µg/L. If patients 
are symptomatic or have markedly elevated levels of 
prolactin (>200 µg/L), this should direct the clinician to 
investigate further; levels >500 µg/L are diagnostic of a 
macroadenoma. Associated galactorrhoea, headaches or 
visual disturbances should alert the clinician to the presence 
of a possible prolactinoma. MRI of the pituitary fossa is 
the gold standard imaging modality for diagnosing pituitary 
adenomas. 
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figure 1.  Magnetic resonance imaging (without gadolinium) of the brain, showing a pituitary macroadenoma measuring 15 mm 
transverse x 10 mm anteroposterior x 7 mm craniocaudal (arrows), without any compression of the optic chiasm and no cavernous 
sinus encasement. a, coronal and B, sagittal t1 weighted images.
A b
